ebola
viru
ebov
negativesens
rna
viru
famili
filovirida
known
caus
sever
hemorrhag
fever
human
primat
infect
ebov
caus
high
mortal
rate
current
fdalicens
vaccin
therapeut
treatment
avail
recent
heatshock
protein
molecular
chaperon
shown
import
host
factor
replic
sever
negativestrand
virus
test
effect
sever
differ
inhibitor
includ
geldanamycin
radicicol
geldanamycin
analog
replic
zair
ebov
result
show
inhibit
significantli
reduc
replic
ebov
classic
inhibitor
reduc
viral
replic
effect
concentr
ec
high
nanomolar
low
micromolar
rang
drug
new
class
inhibitor
show
markedli
potent
inhibit
compound
block
ebov
replic
ec
low
nanomolar
rang
show
signific
potenc
block
replic
primari
human
monocyt
result
valid
import
host
factor
replic
filovirus
suggest
inhibitor
may
therapeut
effect
treat
ebov
infect
ebola
viru
ebov
caus
agent
ebola
hemorrhag
fever
emerg
viral
diseas
caus
sever
hemorrhag
fever
human
nonhuman
primat
nhp
outbreak
occur
africa
mortal
rate
rang
develop
vaccin
therapeut
vital
due
increasingli
frequent
outbreak
placement
ebov
categori
agent
center
diseas
control
prevent
howev
effect
countermeasur
exist
treat
deadli
viral
diseas
ebov
filament
envelop
nonseg
negativesens
rna
viru
famili
filovirida
genom
kb
length
encod
seven
structur
protein
one
nonstructur
protein
follow
order
within
genom
noncod
region
leader
nucleoprotein
np
virion
protein
glycoprotein
sgp
gp
rnadepend
rnapolymeras
rdrp
l
protein
noncod
region
trailer
sanchez
rdrp
share
signific
sequenc
homolog
rdrp
nonseg
negativestrand
rna
virus
requir
viral
transcript
replic
viral
genom
whelan
barr
wertz
common
theme
rdrp
requir
cooper
viral
host
protein
accomplish
replic
andor
transcript
import
host
factor
requir
rdrp
function
identifi
negativestrand
rna
virus
host
factor
requir
ebov
rdrp
function
describ
date
da
et
al
gupta
shaji
banerje
shen
master
strauss
strauss
whelan
barr
wertz
heatshock
protein
molecular
chaperon
guid
fold
intracellular
disposit
proteolyt
turnov
mani
key
regul
cell
growth
differenti
specif
set
client
protein
vivo
steroid
receptor
transcript
factor
protein
kinas
oncogen
pratt
toft
inhibitor
proven
effect
drive
cancer
cell
apoptosi
prevent
proper
fold
oncogen
requir
promot
cancer
cell
growth
sever
inhibitor
phase
ii
clinic
trial
goetz
et
al
whitesel
lindquist
recent
shown
import
host
factor
replic
negativestrand
virus
connor
et
al
addit
inhibit
shown
block
vaccinia
viru
replic
interact
viral
core
protein
cytoplasm
hung
chung
chang
hepat
c
viru
life
cycl
need
proper
cleavag
newli
synthes
hepat
c
protein
ujino
et
al
waxman
et
al
activ
hepat
b
revers
transcriptas
hu
seeger
hu
toft
seeger
stahl
et
al
polio
viru
requir
proper
fold
viral
capsid
protein
inhibitor
show
antivir
activ
geller
et
al
shown
control
viral
polymeras
function
sever
virus
influenza
viru
bind
subunit
rna
polymeras
stimul
activ
momos
et
al
herp
virus
block
significantli
inhibit
viral
replic
presum
due
improp
local
viral
polymeras
burch
weller
li
et
al
flock
hous
viru
activ
prove
import
stabil
local
rna
polymeras
kampmuel
miller
recent
report
inhibitor
impair
replic
sever
prototyp
negativestrand
rna
virus
vesicular
stomat
viru
paramyxoviru
bunyaviru
la
cross
destabil
l
protein
viral
rdrp
connor
et
al
thought
virus
evolv
requir
use
proper
fold
rdrp
connor
et
al
therefor
inhibitor
activ
could
act
broadrang
antivir
agent
specul
hypothesi
would
hold
true
filovirus
therefor
evalu
effect
sever
inhibitor
ebov
replic
natur
product
inhibitor
other
synthet
inhibitor
entir
panel
inhibitor
repres
three
differ
chemic
structur
class
vari
potenc
result
show
inhibitor
significantli
inhibit
replic
ebov
suggest
use
potenti
therapeut
differ
inhibit
ebov
replic
differ
inhibitor
indic
class
inhibitor
may
superior
choic
antivir
agent
result
studi
aid
design
effect
therapeut
treat
ebov
infect
ebov
speci
zair
origin
isol
human
patient
johnson
et
al
passag
twice
vero
cell
use
ebovgreen
fluoresc
protein
gfp
viru
deriv
revers
genet
gener
fulllenth
cdna
clone
insert
report
gene
egfp
towner
et
al
geldanamycin
radicicol
obtain
invivogen
san
diego
ca
lc
lab
woburn
resuspend
dmso
compound
obtain
serenex
pfizer
new
york
ny
resuspend
dmso
compound
screen
use
vero
cell
american
type
cultur
collect
manassa
va
plate
compound
dilut
either
threefold
nm
twofold
ad
plate
one
cohort
allow
incub
compound
infect
plate
infect
low
multipl
infect
moi
ebovgfp
incub
plate
read
ex
em
cutoff
h
post
infect
pi
plate
stain
crystal
violet
read
spectrophotomet
evalu
cytotox
effect
compound
evalu
viru
yieldreduct
assay
use
either
vero
cell
primari
human
monocyt
plate
cell
maintain
modifi
eagl
medium
mem
fetal
bovin
serum
fb
glutamax
invitrogen
carlsbad
ca
medium
remov
cell
infect
zebov
moi
medium
mem
antibiot
contain
follow
drug
concentr
nm
nm
plate
incub
h
rock
everi
min
medium
contain
viru
remov
plate
wash
time
medium
wash
ml
medium
contain
drug
concentr
ad
plate
incub
follow
control
viru
drug
viru
drug
drug
viru
h
pi
medium
collect
titrat
standard
plaqu
assay
vero
cell
analyz
realtim
rtpcr
plaqu
assay
complet
use
confluent
vero
cell
plate
sampl
titrat
serial
dilut
ad
well
plate
incub
h
rock
everi
min
primari
overlay
contain
ebm
fb
agaros
ad
well
plate
incub
day
follow
secondari
overlay
ident
primari
overlay
addit
neutral
red
plaqu
form
unit
pfu
count
day
pi
realtim
rtpcr
assay
use
previous
publish
weidmann
muhlberg
hufert
assay
design
detect
nucleoprotein
gene
ebov
pfu
equival
pfue
determin
use
known
viru
concentr
determin
plaqu
assay
whose
rna
extract
serial
dilut
hand
sensit
assay
pfue
sa
version
sa
institut
inc
cari
nc
use
determin
repeat
measur
anova
viral
replic
sampl
control
treatment
group
time
stepdown
sidak
adjust
multipl
pairwis
comparison
time
point
test
hypothesi
import
host
factor
replic
ebov
investig
effect
sever
differ
inhibitor
replic
ebov
viruspermiss
cell
line
initi
test
effect
increas
concentr
three
differ
inhibitor
geldanamycin
radicicol
compound
extens
histori
use
dissect
function
richter
buchner
repres
two
separ
chemic
class
taldon
sun
chiosi
geldanamycin
benzoquinon
ansamycin
geldanamycin
deriv
current
phase
ii
clinic
trial
anticanc
agent
goetz
et
al
whitesel
lindquist
radicicol
natur
product
monorden
potent
inhibitor
defin
begin
studi
cleveng
blagg
delmott
delmotteplaqu
viral
replic
presenc
absenc
ad
drug
monitor
use
ebov
engin
express
egfp
independ
orf
ebovgfp
viru
allow
track
egfp
fluoresc
robust
indic
viral
replic
towner
et
al
viru
express
gfp
vero
cell
treat
geldanamycin
radicicol
evalu
cell
mocktreat
treat
increas
concentr
drug
nm
infect
viru
min
post
drug
treatment
express
egfp
determin
fluoresc
measur
pi
effect
drug
inhibit
viral
replic
plot
percent
reduct
gfp
fluoresc
reduct
repres
drop
fluoresc
express
fig
three
inhibitor
show
inhibit
viral
replic
time
point
analyz
level
inhibit
vari
compound
greatest
reduct
gfp
observ
h
pi
figur
preincub
compound
slightli
improv
efficaci
inhibit
signific
data
shown
pi
compound
show
maximum
fluoresc
reduct
approxim
ec
rang
nm
radicicol
nm
time
point
radicicol
potent
inhibitor
viral
replic
reach
maximum
reduct
fluoresc
approxim
pi
ec
approxim
nm
geldanamycin
show
weaker
reduct
viral
replic
maximum
reduct
respect
lower
potenc
ec
micromolar
rang
seen
radicicol
see
tabl
cytotox
test
inhibitor
three
drug
show
minim
toxic
concentr
fig
consist
report
minim
toxic
compound
concentr
kampmuel
miller
howev
three
compound
signific
effect
cellular
homeostasi
high
concentr
level
drug
cell
death
rate
observ
suggest
cc
concentr
si
ratio
see
tabl
effect
inhibitor
minim
cytotox
concentr
plot
function
time
inhibit
clear
compound
block
viral
replic
effect
dramat
classic
inhibitor
determin
result
observ
ebovgfp
assay
correl
viral
replic
assay
analyz
compound
yieldreduct
assay
determin
viral
titer
realtim
rtpcr
plaqu
assay
fig
three
inhibitor
observ
reduct
viral
replic
greatest
reduct
viral
replic
pi
compound
geldanamycin
observ
log
pfuml
log
pfueml
log
pfu
ml
log
pfueml
reduct
viru
pi
respect
fig
observ
log
pfuml
log
pfueml
reduct
viru
pi
similar
concentr
drug
fig
radicicol
observ
log
pfuml
log
pfueml
log
pfuml
log
pfueml
reduct
viru
pi
respect
fig
viral
yield
reduct
statist
signific
geldanamycin
radicicol
result
show
good
correl
microtit
plate
assay
yield
reduct
assay
analyz
b
plaqu
assay
interestingli
viral
yield
test
realtim
rtpcr
differ
answer
viral
yield
reduct
obtain
geldanamycin
appear
chang
viral
output
measur
genom
equival
regardless
concentr
inhibitor
use
similarli
concentr
radicicol
show
signific
reduct
genom
equival
produc
infect
thu
realtim
rtpcr
assay
suggest
mark
differ
viral
replic
treatment
plaqu
assay
clearli
show
viral
titer
reduct
suggest
inhibitor
may
caus
bud
replicationdefect
viral
particl
altern
medium
could
still
contain
compound
could
interfer
result
plaqu
assay
data
show
abil
reduc
replic
ebov
also
highlight
inhibitor
show
differ
abil
block
viral
replic
vari
efficaci
compound
led
us
determin
chemic
dissimilar
inhibitor
activ
show
increas
effect
viral
replic
inhibitor
recent
novel
class
benzamid
compound
identifi
inhibitor
determin
antivir
activ
four
compound
vero
cell
primari
human
monocyt
compound
whose
structur
shown
figur
repres
lead
compound
also
publish
snx
huang
et
al
rice
et
al
three
deriv
publish
specif
compound
name
huang
et
al
publish
snx
putcha
et
al
contain
core
structur
see
variou
sidegroup
illustr
tabl
shown
figur
similar
experi
describ
vero
cell
treat
increas
concentr
either
infect
ebovegfp
inhibit
viral
replic
fig
four
compound
show
signific
abil
reduc
viral
gene
express
measur
gfp
product
maximum
reduct
fluoresc
pi
reduct
pi
compound
three
potent
radicicol
geldanamycin
three
compound
test
potent
ec
nm
pi
pi
respect
tabl
similarli
potent
ec
within
rang
nm
nm
pi
well
concentr
cytotox
seen
least
potent
ec
rang
nm
pi
similar
gfpexpress
assay
possibl
primari
monocyt
cell
uniformli
adher
yieldreduct
assay
done
analyz
viral
replic
yieldreduct
assay
vero
cell
determin
two
concentr
drug
one
rel
low
nm
high
assay
show
limit
reduct
viral
titer
fig
howev
yieldreduct
assay
use
human
monocyt
show
much
dramat
effect
monocyt
yieldreduct
assay
cell
treat
either
nm
drug
show
signific
decreas
viral
replic
fig
time
point
pi
show
log
pfueml
reduct
ebov
product
use
nm
high
drug
concentr
littl
evid
replic
drugtreat
monocyt
similar
result
microtit
plate
assay
least
effect
compound
evalu
plaqu
reduct
asay
monocyt
extend
pi
signific
reduct
viral
titer
seen
monocyt
show
compound
highli
effect
block
viral
replic
signific
period
time
drugrel
toxic
note
assay
concentr
drug
concentr
toxic
seen
associ
dmso
prevent
accur
calcul
cc
si
compound
appear
much
specif
potent
classic
inhibitor
develop
therapeut
treat
viral
infect
gener
target
viral
protein
recent
focu
shift
target
host
factor
coopt
use
life
cycl
viru
exampl
chaperon
constitut
abund
fold
enzym
cytosol
shown
play
extens
role
multipl
virus
often
protein
serv
host
factor
bind
viral
protein
prevent
proper
fold
promot
degrad
connor
et
al
nakagawa
et
al
addit
stabil
chaperon
necessari
intracellular
transport
multipl
viral
protein
behavior
exemplifi
revers
transcriptas
hepat
b
polymeras
influenza
viru
hu
et
al
naito
et
al
sever
studi
demonstr
chaperon
promis
target
hostdirect
antivir
develop
sever
smallmolecul
inhibitor
includ
geldanamycin
deriv
origin
character
anticanc
therapeut
reduc
viral
titer
cell
cultur
model
vaccinia
viru
influenza
viru
vesicular
stomat
viru
sever
paramyxovirus
la
cross
viru
hepat
c
viru
banerji
chase
et
al
connor
et
al
hung
chung
chang
nakagawa
et
al
use
inhibitor
antivir
develop
suggest
inhibitor
disrupt
function
viral
polymeras
contrast
use
inhibitor
anticanc
thereapeut
drive
cancer
cell
apoptosi
case
hepat
c
viru
combin
therapi
polyethylen
glycolconjug
interferon
pegifn
plu
inhibitor
show
enhanc
inhibit
viral
replic
liver
infect
mice
compar
pegifn
alon
nakagawa
et
al
show
inhibitor
also
use
inhibitor
ebov
replic
compound
appear
effect
evalu
use
microtit
plate
assay
screen
radicicol
flouorid
benzamid
effect
show
reduct
microtit
plate
screen
assay
vero
cell
detect
inhibitori
activ
microtit
plate
assay
screen
correl
signific
reduct
viral
titer
analysi
show
commerci
avail
inhibitor
geldanamycin
radicicol
less
potent
inhibitor
ebov
benzamid
analog
tabl
differ
potenc
inhibit
observ
ebola
viru
also
negativestrand
rna
virus
j
connor
unpublish
observ
result
suggest
inhibitor
differ
structur
vari
efficaci
differ
viral
pathogen
could
due
inher
potenc
inhibit
differ
compound
compound
target
differ
holoenzym
addit
differ
cell
line
may
differ
level
ident
protein
within
complex
known
alter
atpbind
pocket
pearl
prodrom
drug
test
bound
result
point
fluorid
benzamid
compound
test
promis
compound
blockag
pertin
ebovrequir
complex
benzamid
compound
strong
antivir
activ
primari
human
monocyt
monocyt
known
import
earli
target
ebov
replic
geisbert
et
al
thu
signific
antivir
effect
compound
cell
suggest
might
particularli
effect
inhibitor
viral
replic
vivo
mechan
action
inhibitor
ebov
remain
determin
possibl
inhibitor
caus
degrad
viral
polymeras
observ
negativestrand
rna
virus
connor
et
al
howev
given
result
use
geldanamycin
show
treat
cell
show
lower
level
egfp
product
lower
infecti
viral
yield
similar
bud
viral
genom
untreat
cell
inhibit
may
also
import
proper
bud
infecti
ebov
role
replic
sever
virus
import
topic
research
regard
therapeut
develop
effect
countermeasur
current
exist
ebov
result
offer
insight
possibl
futur
develop
potenti
therapeut
treat
deadli
diseas
result
benzamid
inhibitor
suggest
compound
promis
class
inhibitor
antivir
activ
ebov
futur
work
laboratori
investig
role
play
ebov
replic
well
neg
strand
rna
virus
effect
inhibitor
geldanamycin
radidicol
replic
ebovgfp
dose
respons
curv
geldanamycin
close
circl
close
squar
radicicol
close
triangl
pi
b
pi
c
pi
pi
plot
percent
decreas
fluoresc
signal
compar
dimethylsulfoxidetr
control
infect
result
show
decreas
percent
gfp
reduct
increas
concentr
compound
toxic
timecours
geldanamycin
radidicol
ebovgfp
infect
cell
toxic
determin
evalu
viabl
cell
crystal
violet
stain
percentag
surviv
cell
h
drug
treatment
plot
b
reduct
viral
replic
plot
timecours
compound
test
nm
nm
yieldreduct
assay
supernat
analyz
plaqu
assay
c
e
realtim
rtpcr
b
f
pfuplaqueform
unit
pfueplaqueform
unit
equival
effect
novel
inhibitor
geldanamycin
radidicol
replic
ebovgfp
dose
respons
curv
pi
b
pi
c
pi
pi
compound
test
nm
yieldreduct
assay
vero
b
monocyt
supernat
analyz
realtim
rtpcr
